To investigate the development of mesenteric panniculitis (MP) following treatment with BRAF/MEK inhibitors (BRAFi/MEKi) and immune checkpoint inhibitors (ICI) in melanoma patients, highlighting its clinical significance.
Key Findings:
Increased incidence of mesenteric panniculitis reported in patients treated with BRAFi/MEKi, with specific incidence rates provided.
MP prevalence in the general population is between 0.16% and 3.4%, with references to studies supporting these statistics.
MP can mimic underlying malignancies, necessitating careful imaging interpretation, with examples of misdiagnosis.
Interpretation:
The study suggests a potential link between BRAFi/MEKi treatment and increased incidence of MP, emphasizing the need for awareness among clinicians to avoid misdiagnosis and improve patient outcomes.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
Limited cohort size for BRAFi/MEKi group may affect generalizability, suggesting the need for larger studies.
Lack of long-term follow-up data on MP outcomes, indicating a gap in understanding the long-term implications of MP.
Conclusion:
The findings indicate that BRAFi/MEKi therapies may be associated with a higher incidence of mesenteric panniculitis, warranting further investigation in larger cohorts, particularly focusing on long-term outcomes and mechanisms.
by Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, Marcel Opitz, Denise Bos, Lisa Zimmer, Selma Ugurel, Johannes Haubold, Dirk Schadendorf, Elisabeth Livingstone, Benedikt M. Schaarschmidt
